Upon completion of this activity, the participants should be able to:

• Advance Multidisciplinary Care in Lung Cancer: Make use of evidence-based strategies across surgery, radiation, medical oncology, pathology, radiology, nursing, and supportive care to optimize outcomes for patients with lung cancer.
• Evaluate Innovations in Screening, Early Detection, and Risk Reduction: Assess advances in lung cancer screening programs, novel imaging, and the role of prevention strategies—including tobacco control and occupational risk mitigation—to reduce disease burden.
• Implement Personalized Treatment Approaches: Apply current evidence on molecular testing, biomarker-driven therapies, and targeted treatments—including ADCs, TKIs, and immunotherapies—to tailor interventions for diverse patient populations.
• Explore the Evolving Landscape of Immunotherapy: Critically evaluate emerging data on immune checkpoint inhibitors, combination strategies, bispecifics, and their management in special populations such as patients with autoimmune diseases, transplants, or brain metastases.
• Enhance Management of Early and Locally Advanced Disease: Discuss best practices and evolving approaches for resectable and unresectable NSCLC, including neoadjuvant, adjuvant, and perioperative strategies, as well as advanced radiotherapy and ablative techniques.
• Address Challenges in SCLC, NENs, and Rare Thoracic Tumors: Examine new diagnostic, molecular, and therapeutic developments in small cell lung cancer, neuroendocrine tumors, mesothelioma, and thymic malignancies to improve patient care.
• Integrate Novel Diagnostic and Monitoring Tools: Evaluate the utility of advanced imaging, multiomic analyses, liquid biopsies (including ctDNA and methylation), and digital pathology in staging, treatment response, and surveillance.
• Improve Care Delivery in Resource-Limited and Diverse Settings: Identify barriers and implement solutions for equitable access to molecular testing, precision oncology, and advanced therapies in low- and middle-income countries and underserved populations.
• Promote Shared Decision-Making and Patient-Centered Care: Model approaches to communication, survivorship planning, and addressing quality of life, emphasizing patient preferences, advocacy, and integrative care.
• Foster Interactive Learning and Collaborative Problem-Solving: Apply new knowledge to complex clinical scenarios and enhance decision-making in lung cancer care by engaging in case-based discussions, polling, and multidisciplinary debates.

Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements:

Physicians
The International Association for the Study of Lung Cancer designates the “other activity” (a live conference offered in a hybrid format including recorded virtual participation) format for this educational activity for a maximum of 55.0 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

If you attended World Conference on Lung Cancer 2026, you may access the conference materials by clicking this button.

If you did not attend World Conference on Lung Cancer 2026, you may purchase access to the conference materials by clicking this button.